Aryl acylsulfonamides as BLT1 antagonists

A compound of structural formula I:

• or a pharmaceutically acceptable salt thereof;
• wherein
• A is selected from the group consisting of:
• (1) aryl, and
• (2) heteroaryl,
• wherein aryl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C1-6alkyl and halogen;
• B is selected from the group consisting of:
• (1) aryl, and
• (2) heteroaryl,
• wherein aryl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C1-6alkyl and halogen;
• X is selected from the group consisting of:
• (1) —C(O)NHSO2CF3,
• (2) —C(O)NHSO2CH2CF3,
• (3) —C(O)NHSO2CHF2,
• (4) —C(O)NHSO2C1-6alkyl,
• (5) —C(O)NHSO2CH2C3-6cycloalkyl, and
• (6) —C(O)NHSO2C3-6cycloalkyl,
• wherein alkyl and cycloalkyl are unsubstituted or substituted with 1-3 substituents independently selected from C1-6alkyl;
• Z is selected from the group consisting of:
• (1) heteroaryl,
• (2) C2-6cycloheteroalkyl, and
• (3) C3-6cycloalkyl,
• wherein heteroaryl, cycloheteroalkyl and cycloalkyl are unsubstituted or substituted with 1-4 substituents independently selected from C1-6alkyl;
• Ra is selected from the group consisting of:
• (1) hydrogen,
• (2) halogen, and
• (3) C1-6alkyl;
• and
• Rb is selected from the group consisting of:
• (1) hydrogen,
• (2) halogen, and
• (3) C1-6alkyl.